Catatonia in French psychiatry: Implications of the zolpidem challenge test

Psychiatric Annals

Volumn 37, Issue 1, 2007, Pages 45-54

  Thomas, Pierre ^a,b   Cottencin, Olivier ^a   Rascle, Claire ^a   Vaiva, Guillaume ^a   Goudemand, Michel ^a   Bieder, Jacques ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847266793     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20070101-02     Document Type: Review

References (58)

1. Kahlbaum KL. Die Catatonie oder das Spannungsirresein, Berlin, Kirschwald 1874. Translated by Viallard A. La catatonie ou folie tonique. Evol Psychiatr. 1987;52(2):370.
2. Baillarger J. Stupidité des aliénés. Annales médico-psychologiques du système nerveux. 1844.
3. Delasiauve L, Traìté de l'épilepsie. Histoire, traitement, médecine légale. Paris Masson. 1854
4. Baruk H. Experimental catatonia and psychopharmacology. Therapie. 1972;27(1):119-131
5. Kraepelin E. Dementia Praecox and Paraphrenia. Barclay RM, trans. Edinburgh: E&S. Livingstone; 1919:132.
6. Séglas J, Chaslin P. Katatonia. Brain. 1889;12:191-232
7. Bleuler E. Démence Précoce ou groupe des Schizophrénies. Viallard A, trans. Paris: EPEL, 1998.
8. Ey H. Études Psychiatriques. Paris; Desclée de Brouwer, 1950;2:69-162.
9. Blumer D. Catatonia and the neuroleptic: psychobiologic significance of remote and recent findings. Compr Psychiatry. 1997;38(4):193-201.
10. Gelenberg AJ. The catatonic syndrome. Lancet. 1976;19:1339-1341.
11. Taylor MA. Catatonia. A review of a behavioral neurologic syndrome. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 1990;3:48-72.
12. Morrison JR. Catatonia. Retarded and excited types. Arch Gen Psychiatry. 1973;28:39-41.
13. Carroll BT, Kennedy JC, Goforth HW. Catatonic signs in medical and psychiatric catatonias. CNS Spectrums. 2000;5(7):66-69.
14. Salam SA, Pillai AK, Beresford TP. Lorazepam for psychogenic catatonia. Am J Psychiatry. 1987;144(8):1082-1083.
15. Ripley TL, Millson RC. Psychogenic catatonia treated with lorazepam. Am J Psychiatry. 1988; 145(6):764-765.
16. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51(9):357-362.
17. Ungvari GS, Leung HC, Lee TS. Benzodiazepines and the psychopathology of catatonia. Pharmacopsychiatry. 1994;27(6):242-245.
18. Ungvari GS, Chiu HFK, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology. 1999;142(4):393-398.
19. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavia. 1996;93(2):129-136.
20. Yassa R, Iskandar H, Lalinec M. Lorazepam as an adjunct in the treatment of catatonic states : an open clinical trial. J Clin Psychopharmacol. 1990;10(1):66-68.
21. Lee JW, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Ann Clin Psychiatr. 2000;12(2):89-96.
22. Fink M, Taylor MA. Catatonia. A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press, Cambridge: 2003.
23. Mastain B, Vaiva G, Guerouaou D, Pommery J, Thomas P. Effet favorable du zolpidem sur un état catatonique. Rev Neurologique. 1995;1:52-56.
24. Mastain B, Rascle C, Thomas P. Goudemand M. Zolpidem in catatonic syndrome: from pharmacological test to a pathophysiological hypothesis. Movement Disorders. 1998;13:46.
25. Rascle C, Thomas P, Maron M, et al. Catatonia relief with zolpidem: An open study. Eur Neuropsychopharmacol. 1997;7:277.
26. Thomas P, Rascle C, Mastain B, Maron M, Vaiva G. Test for catatonia with zolpidem. Lancet. 1997;369(9053):702.
27. Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet. 1997;349(9069):1914.
28. Cottencin O, Thomas P, Vaiva G, Rascle C, Goudemand M. A case of agitated catatonia. Pharmacopsychiatry. 1999;32(1):38-40.
29. Cottencin O, Debien C, Vaiva G, Thomas P, Pruvot FR. Catatonia and liver transplant. Psychosomatics. 2002;43(4):338-339.
30. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290(5489):131-134.
31. Rudolph U, Crestani F, Moehler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 2001;22(4):188-194.
32. Langer SZ, Arbilla S, Scatton BV, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpidem. In: Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders: a Novel Experimental and Therapeutic Approach. Raven Press, New York, 1988:55-70.
33. Kang-Park MH, Wilson WA, Moore SD. Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei. Neuropharmacology. 2004;46(1):1-9.
34. Crestani F, Martin J, Moehler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000;131(7):1251-1254.
35. Mohler H, Fritschy JM, Crestani F, Hensch T, Rudolph U. Specific GABA(A) circuits in brain development and therapy. Biochem Pharmacol 2004;15(8): 1685-90.
36. Langtry HD, Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs. 1990;40(2):291-313.
37. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor al subtype. Nat Neurosci. 2000;3(6):587-593.
38. Cohen AS, Lin DD, Coulter DA. Inhibitory synaptic transmission in rat hippo-campal area CA1 neurons. J Neurophysiol. 2000;84(5):2465-76.
39. Vicini S, Ferguson C, Prybylowski K, Kralic J, Morrow AL, Homanics GE. GABA(A) receptor alpha 1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J Neurosci. 2001;21(9):3009-16.
40. Defazio RA, Hablitz JJ. Reduction of zolpidem sensitivity in a freeze lesion model of neocortical dysgenesis. J Neurophysiol. 1999;81(1):404-7
41. Daniele A, Albanese A, Gainotti G, Gregori B, Bartolomeo P. Zolpidem in Parkinson's disease. Lancet. 1997;349(9060):1222-1223.
42. Ruzicka E, Roth J, Jech R, Busek P. Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Mov Disord. 2000;15:734-735.
43. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. 1999;341(7):543-544.
44. Mayr B, Bonelli R, Niederwieser R, Koltringer P, Reisecker F. Zolpidem in progressive supranuclear palsy. European Journal of Neurology. 2002;9(2);184.
45. Garretto NLS, Bueri J, Rey R, Arakaki T, Nano V, Mancuso M. Improvement of blepharospasm with zolpidem. Movement Disorders. 2004;19(8):967-968.
46. Farver DK, Khan MH. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother. 2001;35(4):435-437.
47. Bezerra ML, Martinez JV. Zolpidem in restless legs syndrome. Eur Neurol. 2002;48(3):180-181.
48. Shadan FF, Poceta JS, Kline LE. Zolpidem for postanoxic spasticity. South Med J. 2004;97(8):791-792.
49. Evidente VG. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology. 2002;58(4):662-663.
50. Jackson CW, Pitner JK, Mintzer JE. Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry. 1996;57(8):372-373.
51. Jonville-Bera AP, Autret-Leca E. Beneficial effect of zolpidem for dementia. Ann Pharmacother. 2002;36(11):1808.
52. Chen L. Chan CS, Yung WH. Electro-physiological and behavioral effects of zolpidem in rat globus pallidus. Exp Neurol. 2004;186(2):212-220.
53. Berardelli A, Rothwell JC, Hallett M, et al. The pathophysiology of primary dystonia. Brain. 1998;121(Pt 7): 1195-1212.
54. Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary arousal from semi-comatose state on zolpidem. A case report. 5 Afr Med J. 2000;90(1):68-72.
55. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med. 2004;351(5):511-512.
56. Clauss RP, Nel WH. Effect of zolpidem on brain injury and diaschisis as detected by 99mTc HMPAO brain SPECT in humans. Arzneimittelforschung. 2004;54(10):641-646.
57. Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation. 2006;21(1):23-8.
58. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med. 2004;350(9):949-950.